
==== Front
J Hematol Oncol
J Hematol Oncol
Journal of Hematology & Oncology
1756-8722
BioMed Central London

39256814
1603
10.1186/s13045-024-01603-z
Correspondence
Outcome after short exposure to tyrosine kinase inhibitors in pregnant female patients with chronic myeloid leukemia
Zu Yingling 1
Zhao Huifang 1
Chen Jianling 2
Dang Huibing 3
Shi Yanrong 4
Liang Lixin 5
Mei Shuhao 6
Song Yongping songyp@zzu.edu.cn

7
Zhang Yanli 13203729690@163.com

1
1 https://ror.org/043ek5g31 grid.414008.9 0000 0004 1799 4638 Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, 450008 China
2 https://ror.org/042g3qa69 grid.440299.2 Department of Hematology, Pingdingshan the Second People’s Hospital, Pingdingshan, Henan, 467000 China
3 https://ror.org/03j450x81 grid.507008.a 0000 0004 1758 2625 Department of Hematology, The First Affiliated Hospital of Nanyang Medical College, Nanyang, Henan, 473000 China
4 Department of Hematology, General Hospital of Pingmei Shenma Medical Group, Pingdingshan, Henan, 467000 China
5 Department of Hematology, Sanmenxia Central Hospital, Sanmenxia, Henan, 472000 China
6 https://ror.org/04cr34a11 grid.508285.2 0000 0004 1757 7463 Department of Hematology, Xuchang Central Hospital, Xuchang, Henan, 461000 China
7 https://ror.org/056swr059 grid.412633.1 Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052 China
11 9 2024
11 9 2024
2024
17 828 7 2024
30 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Unintended pregnancy for female patients with chronic myeloid leukemia (CML) raises the discussion of treatment choices due to the teratogenicity of tyrosine kinase inhibitor (TKI). We report 51 accidental pregnant CML chronic phase (CP) patients with TKI withdrawal immediately after pregnancy from December 2010 to February 2024 to observe the effect of short exposure to TKI on the fetus and the infant outcomes. 59 pregnancies resulted in 100% normal childbirth without birth abnormalities. The median TKI exposure duration was 4 (4–20) weeks in 58 pregnancies, and one pregnancy avoided TKI exposure due to treatment discontinuation of the patient with treatment-free remission (TFR). All newborns had normal birth weight except one premature infant with low birth weight less than the 10th percentile. Up to now, all the children are in good health. 13 (25.5%) and 30 (58.8%) patients had achieved major molecular response (MMR) and deep molecular response (DMR) at pregnancy, respectively. After TKI discontinuation, loss of MMR and complete hematologic response occurred in 6 (46.2%) and 2 (25.0%) patients at delivery, respectively. 38 patients resumed TKI treatment after delivery, and 13 patients without DMR loss sustained TFR after delivery. The median time to regain MMR and DMR were 3 (2–6) months and 6 (1–28) months, respectively. These results demonstrate that TKI discontinuation during pregnancy is feasible for CML-CP patients, and short TKI exposure of pregnant patients has little influence on children’s growth and development.

Keywords

Tyrosine kinase inhibitor
Pregnancy
Short exposure
Chronic myeloid leukemia
Henan provincial Medical Science and Technology Research Project232102311143 Provincial and Ministry Joint Co-construction Project of Henan Medical Science and Technology Research PlanSBGJ202103034 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcTo the Editor.

In the era of tyrosine kinase inhibitor (TKI), improving the quality of life has become main therapeutic goal for patients with chronic myeloid leukemia (CML). Fertility is an extremely important issue. Due to the recognized teratogenicity of TKIs, female pregnant patients with CML are recommended to discontinue TKI [1]. Nevertheless, patients with unintended pregnancy have the risk of short TKI exposure. The adverse effects of short exposure to TKI on the fetus and the infant are still unclear. We retrospectively observed the data of accidental pregnancy in 51 patients stopping TKI immediately after pregnancy from December 2010 to February 2024.

The median ages of patients at CML diagnosis and pregnancy were 22 (12–38) years and 28 (18–40) years. All patients had CML chronic phase at pregnancy and the majority (68.6%) was low Sokal score. TKI therapy at the first pregnancy included imatinib (45.1%), nilotinib (43.1%), dasatinib (5.9%) and flumatinib (5.9%). The median duration from diagnosis to the first pregnancy was 60 (8-185) months, and the duration of TKI treatment was 48 (8-132) months. The characteristics of patients is depicted in Table 1.

Table 1 The characteristics of pregnant female patients with CML

Parameter	Median [range] or N (%) Total N = 51	
Age at CML diagnosis (years)	22 (12–38)	
Sokal score		
 Low risk < 0.8

 Intermediate risk 0.8–1.2

	35 (68.6)

16 (31.4)

	
Duration from diagnosis to the first pregnancy (months)	60 (8−185)	
TKI treatment at the first pregnancy		
 Imatinib

 Nilotinib

 Dasatinib

 Flumatinib

	23 (45.1)

22 (43.1)

3 (5.9)

3 (5.9)

	
Duration of TKI treatment (months)	48 (8−132)	
TKI exposure before the first pregnancy (weeks)	4 (4–20)	
Disease status at pregnancy		
 without MMR

 MMR

 DMR

	8 (15.7)

13 (25.5)

30 (58.8)

	
Disease status at delivery		
 without MMR

 MMR

 DMR

	14 (27.5)

13 (25.5)

24 (47.1)

	
Time of pregnancy		
 One

 Two

 Three

	44 (86.3)

6 (11.8)

1 (1.9)

	
Restart TKI treatment		
 yes

 no

	38 (74.5)

13 (25.5)

	
Time of restart TKI treatment after delivery (days)	7 (1−120)	
Disease status at follow-up		
 without MMR

 MMR

 DMR

	8 (15.7)

18 (35.3)

25 (49.0)

	
CML chronic myeloid leukemia, TKI tyrosine kinase inhibitor, MMR major molecular response, DMR deep molecular response

Data of 59 pregnancies in 51 patients was available. TKI exposure before pregnancy was 4 (4–20) weeks, the majority within 8 weeks but one in 20 weeks. Retrospective studies showed embryotoxicity and teratogenicity were induced by imatinib and dasatinib [2, 3]. There is few reports about the effects of nilotinib and flumatinib on the fetus. However, whether short TKI exposure could be safe is a controversial subject. It is worth mentioning that a 18-years old patient had a healthy baby after exposure to dasatinib for 20 weeks.

Fifty-nine pregnancies resulted in live births. The median height of newborns was 50 (46–54) cm, and the median weight was 3200 (2050–4280) g. Only one newborn who premature at week 36 had a low birth weight less than the 10th percentile, exposed to nilotinib in first 4 weeks of pregnancy. Nevertheless, the infant recovered normal weight by the second month without medical intervention. 20 (33.9%) newborns were breastfed for median 5(2–10) months, and mothers continued treatment-free observation during breastfeeding. Baby colostrum, the first 2–5 days postpartum, could be conducive to immune system of newborn. Thus, short-term breastfeeding was recommended even the patient with need to restart TKI [4, 5]. None of congenital malformations, abnormal liver function and hematological indices were observed. Different doses of imatinib and dasatinib resulted in various embryo-fetal toxicity [6, 7]. Whether none congenital malformations is associated with unreached teratogenic dose due to short exposure to TKIs is the next to be studied. The median follow-up was 47 (3-124) months and all are generally in good health to date (Table 2).

Table 2 Newborns characteristics and outcomes

Parameter	Median [range] or N (%) Total N = 59	
Gender		
 Male

 Female

	33 (55.9)

26 (44.1)

	
Delivery mode		
 Natural delivery

 Caesarean section

	12 (20.3)

47 (79.7)

	
Gestational age		
 Full term

 premature delivery

	58 (98.3)

1 (1.7)

	
Breast feeding		
 Yes

 No

	20 (33.9)

39 (66.1)

	
Birth weight		
 Normal weight

 Low weight

	58 (98.3)

1 (1.7)

	
Median height (cm)	50 (46–54)	
Percentilea at birth		
 < 10

 25–75

	1 (1.7)

58 (98.3)

	
Median follow-up, months	47 (3−124)	
aCalculated according to INTERGROWTH-21st Project tables

In terms to the outcomes, all patients are still alive now. 13 (25.5%) and 30 (58.8%) patients had achieved major molecular response (MMR) and deep molecular response (DMR, BCR-ABL < 0.01%) at pregnancy, respectively. 20% (6/30) and 46.2% (6/13) of patients lost DMR and MMR at delivery. But none with initial DMR lost MMR. The median time of DMR and MMR loss was 3 (2–4) months and 6 (5–7) months. Two experienced loss of complete hematologic response. No difference in resistance rate to front-line treatment was found between patients with or without therapy during pregnancy [8]. Interestingly enough, three patients with MMR at pregnancy achieved DMR after 7 months without TKI therapy. The regenerative dynamics of residual CML in pregnant women maybe distinct from that in non-pregnant patients [9]. Despite low tumor burden, immune surveillance systems maybe committed to control disease with untreated based on deep level of response [10]. Further studies evaluating the correlation of pregnancy and immune surveillance should be consider. TKI reinitiated in 38 patients, and the median time was 30 (1-366) days after delivery. Treatment-free remission (TFR) was chosen in 13 patients without DMR loss after delivery. 42.9% (6/14) and 53.8% (7/13) patients regained MMR and DMR, which might mean that the conceiving in DMR for female patients was safer than that in MMR. The median times to regain MMR and DMR were 3 (2–6) months and 6 (1–28) months, respectively.

Although a limited number of patients, our results suggest that short exposure to TKI is promising to normal pregnancy and growth of children, facilitating the balance between TKI treatment and pregnancy.

Acknowledgements

We thank all the patients, their families, and the institutions involved in this study.

Author contributions

YLZ contributed in the data collection, statistical analysis, and writing of the manuscript. HFZ did the data collection and edited the manuscript. JLC, HBD, YRS, LXL and SHM took part in the data collection. YPS and YLZ participated in the study design and manuscript editing. All authors read and approved the final manuscript.

Funding

This work was supported by Henan provincial Medical Science and Technology Research Project (232102311143, YL. Zu), Provincial and Ministry Joint Co-construction Project of Henan Medical Science and Technology Research Plan (SBGJ202103034, YL. Zu).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of the Affiliated Cancer Hospital of Zhengzhou University. Written informed consent was secured from all participating patients.

Consent for publication

All patients signed written informed consent for treatment, data collection and usage of data for clinical research in accordance with modified Declaration of Helsinki.

Competing interests

The authors declare no competing interests.

Abbreviations

TKI Tyrosine kinase inhibitor

CML Chronic myeloid leukemia

TFR Treatment-free remission

DMR Deep molecular response

MMR Major molecular response

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yingling Zu and Huifang Zhao contributed equally to this work.
==== Refs
References

1. Berman E Druker BJ Burwick R Chronic myelogenous leukemia: pregnancy in the era of stopping tyrosine kinase inhibitor therapy J Clin Oncology: Official J Am Soc Clin Oncol 2018 36 1250 6 10.1200/JCO.2017.77.2574
Berman E, Druker BJ, Burwick R. Chronic myelogenous leukemia: pregnancy in the era of stopping tyrosine kinase inhibitor therapy. J Clin Oncology: Official J Am Soc Clin Oncol. 2018;36:1250–6.10.1200/JCO.2017.77.2574
2. Cortes JE Abruzzese E Chelysheva E Guha M Wallis N Apperley JF The impact of dasatinib on pregnancy outcomes Am J Hematol 2015 90 1111 5 10.1002/ajh.24186 26348106
Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90:1111–5.26348106 10.1002/ajh.24186
3. Pye SM Cortes J Ault P Hatfield A Kantarjian H Pilot R The effects of imatinib on pregnancy outcome Blood 2008 111 5505 8 10.1182/blood-2007-10-114900 18322153
Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111:5505–8.18322153 10.1182/blood-2007-10-114900
4. Abruzzese E Mauro M Apperley J Chelysheva E Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations Therapeutic Adv Hematol 2020 11 2040620720966120
Abruzzese E, Mauro M, Apperley J, Chelysheva E. Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. Therapeutic Adv Hematol. 2020;11:2040620720966120.
5. Chelysheva E Aleshin S Polushkina E Shmakov R Shokhin I Chilov G Breastfeeding in patients with chronic myeloid leukaemia: Case Series with measurements of drug concentrations in maternal milk and literature review Mediterranean J Hematol Infect Dis 2018 10 e2018027 10.4084/mjhid.2018.027
Chelysheva E, Aleshin S, Polushkina E, Shmakov R, Shokhin I, Chilov G, et al. Breastfeeding in patients with chronic myeloid leukaemia: Case Series with measurements of drug concentrations in maternal milk and literature review. Mediterranean J Hematol Infect Dis. 2018;10:e2018027.10.4084/mjhid.2018.027
6. He K Lago MW Iyer RA Shyu WC Humphreys WG Christopher LJ Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats Drug Metab Dispos 2008 36 2564 70 10.1124/dmd.108.022764 18787054
He K, Lago MW, Iyer RA, Shyu WC, Humphreys WG, Christopher LJ. Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab Dispos. 2008;36:2564–70.18787054 10.1124/dmd.108.022764
7. El Gendy MM Kandil AM Helal MA Zahou FM The teratogenic effects of imatinib mesylate on rat fetuses Toxicol Rep 2015 2 654 63 10.1016/j.toxrep.2015.05.001 28962401
El Gendy MM, Kandil AM, Helal MA, Zahou FM. The teratogenic effects of imatinib mesylate on rat fetuses. Toxicol Rep. 2015;2:654–63.28962401 10.1016/j.toxrep.2015.05.001
8. Chelysheva E Apperley J Turkina A Yassin MA Rea D Nicolini FE Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry Leukemia 2024 38 788 95 10.1038/s41375-024-02183-0 38388649
Chelysheva E, Apperley J, Turkina A, Yassin MA, Rea D, Nicolini FE, et al. Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry. Leukemia. 2024;38:788–95.38388649 10.1038/s41375-024-02183-0
9. Chelysheva E, Turkina A, Rea D, Rousselot P, Nicolini FE, Trawinska MM et al. Pregnancy outcome in female patients with chronic myeloid leukemia worldwide: analysis of 305 cases of the European Leukemia Net registry. HemaSphere. 2019;3(Suppl. 1):395-6.
10. Chamoun K Kantarjian H Atallah R Gonzalez GN Issa GC Rios MB Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience J Hematol Oncol 2019 12 1 10.1186/s13045-018-0686-1 30606227
Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, et al. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol. 2019;12:1.30606227 10.1186/s13045-018-0686-1
